Idexx Laboratories (IDXX) AI Stock Analysis

• Market Cap: $57.66B
• Dividend Yield: N/A
• Average Volume (3M): 461.44K
• Price to Earnings (P/E): 57.2
• Beta (1Y): 1.07
• Revenue Growth: 8.39%
• EPS Growth: 21.44%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.40
• Shares Outstanding: 79,851,330
• 10 Day Avg. Volume: 611,295
• 30 Day Avg. Volume: 461,437
• PEG Ratio: 6.51
• Price to Book (P/B): 21.37
• Price to Sales (P/S): 8.75
• P/FCF Ratio: 42.72
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 12.59
• Enterprise Value/Gross Profit: 20.39
• Enterprise Value/Ebitda: 36.12
• 1Y Price Target: $777.22
• Price Target Upside: 7.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): 12.62
• Revenue Forecast (FY): $4.27B

• Rating: 78 Outperform
• Price Target: $823.00 ▲(14.27% Upside)

Idexx Laboratories demonstrates strong financial performance and positive earnings call sentiment, driving the overall score. The technical analysis indicates a strong upward trend, though the high valuation and overbought RSI suggest caution. The company's strategic focus on innovation and international growth supports its robust outlook.

Positive Factors

Revenue Growth

Consistent revenue growth driven by strong performance in CAG Diagnostics and international markets indicates robust market demand and effective strategic execution.

Innovation Strategy

IDEXX's focus on innovation, such as the launch of IDEXX Cancer Dx and new diagnostic capabilities, strengthens its competitive position and supports long-term growth.

Cash Flow Management

Effective cash generation and management provide the company with the financial flexibility to invest in growth opportunities and sustain operations.

Negative Factors

Decline in U.S. Clinical Visits

A decline in U.S. clinical visits may impact future revenue growth in the domestic market, posing a challenge to maintaining current growth rates.

Foreign Exchange Impact

Foreign exchange volatility can affect profitability, potentially impacting margins and financial performance in the long term.

Rapid Assay Revenue Decline

A shift in testing platforms leading to a decline in rapid assay revenues could indicate challenges in adapting product lines to market needs.

Idexx Laboratories Business Overview & Revenue Model

Company Description

IDEXX Laboratories, Inc. is a global leader in veterinary diagnostics, water testing, and dairy and food safety. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX primarily serves the veterinary market with innovative products and services that enhance the health and well-being of pets. The company operates in several segments, including Companion Animal Group, Livestock, Poultry, and Dairy, as well as Water and Food Testing. Its core products include diagnostic tests, instruments, and software solutions that facilitate rapid and accurate disease diagnosis and management.

How the Company Makes Money

IDEXX Laboratories generates revenue through multiple key streams, primarily focusing on its diagnostic products and services for the veterinary market. The Companion Animal Group represents the largest segment, contributing significantly to revenue through the sale of point-of-care diagnostic tests, laboratory services, and related software. The company also earns revenue from its Livestock, Poultry, and Dairy segment, which provides diagnostic solutions for animal health and food safety. Additionally, IDEXX's Water and Food Testing segment contributes to its earnings through advanced testing solutions that ensure public health and safety. IDEXX's revenue model is supported by recurring sales from consumables associated with its diagnostic instruments, which fosters customer loyalty and ongoing revenue. The company benefits from strategic partnerships with veterinary clinics and animal health organizations, enhancing its market presence and driving sales growth.

Idexx Laboratories Financial Statement Overview

Summary

Idexx Laboratories exhibits a strong financial profile with consistent revenue and profit growth, efficient cost management, and robust cash flow generation. The balance sheet reflects a balanced approach to leverage, supporting long-term stability. While the company shows slight fluctuations in growth rates, its overall financial health remains solid.

Income Statement

Idexx Laboratories demonstrates strong financial performance with consistent revenue growth and robust profit margins. The TTM data shows a Gross Profit Margin of 61.54% and a Net Profit Margin of 24.41%, indicating efficient cost management and profitability. The EBIT and EBITDA margins are also healthy, reflecting strong operational efficiency. The revenue growth rate of 3.21% in the TTM period suggests steady growth, although slightly lower than previous years.

Balance Sheet

The balance sheet shows a moderate Debt-to-Equity Ratio of 0.85 in the TTM period, indicating a balanced approach to leverage. The Return on Equity is impressive at 64.42%, showcasing strong profitability relative to shareholder equity. However, the Equity Ratio of 46.10% suggests a moderate reliance on debt financing. Overall, the company maintains a stable financial position with effective use of equity.

Cash Flow

Cash flow analysis reveals a strong Free Cash Flow Growth Rate of 23.15% in the TTM period, indicating effective cash generation. The Operating Cash Flow to Net Income Ratio of 1.06 and Free Cash Flow to Net Income Ratio of 0.85 reflect efficient cash conversion from earnings. The company demonstrates solid cash flow management, supporting its operational and strategic initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.17B	3.90B	3.66B	3.37B	3.22B	2.71B
Gross Profit	2.57B	2.38B	2.19B	2.00B	1.89B	1.57B
EBITDA	1.45B	1.28B	1.22B	1.01B	1.04B	793.81M
Net Income	1.03B	887.87M	845.04M	679.09M	744.85M	581.78M
Balance Sheet
Total Assets	3.39B	3.29B	3.26B	2.75B	2.44B	2.29B
Cash, Cash Equivalents and Short-Term Investments	208.17M	288.27M	453.93M	112.55M	144.45M	383.93M
Total Debt	1.11B	986.95M	1.07B	1.47B	1.03B	1.00B
Total Liabilities	1.83B	1.70B	1.78B	2.14B	1.75B	1.66B
Stockholders Equity	1.56B	1.60B	1.48B	608.74M	689.99M	632.09M
Cash Flow
Free Cash Flow	953.57M	798.08M	772.88M	394.15M	636.00M	540.44M
Operating Cash Flow	1.09B	929.00M	906.51M	542.98M	755.55M	648.06M
Investing Cash Flow	-147.95M	-207.06M	-125.25M	-195.35M	-292.97M	-109.38M
Financing Cash Flow	-1.04B	-878.07M	-442.00M	-370.94M	-697.41M	-248.42M

Idexx Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 720.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXX, the sentiment is Positive. The current price of 720.21 is above the 20-day moving average (MA) of 647.68, above the 50-day MA of 642.60, and above the 200-day MA of 531.00, indicating a bullish trend. The MACD of 16.18 indicates Negative momentum. The RSI at 74.81 is Negative, neither overbought nor oversold. The STOCH value of 88.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXX.

Idexx Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	79 Outperform	$41.41B	34.26	19.88%	0.68%	4.48%	-11.52%
IDXX	78 Outperform	$57.66B	57.24	64.63%	―	8.39%	21.44%
ILMN	73 Outperform	$17.86B	26.18	31.20%	―	-2.39%	―
ZTS	70 Outperform	$55.16B	20.97	49.87%	1.66%	2.68%	11.51%
ELAN	69 Neutral	$11.18B	24.75	6.83%	―	-0.18%	―
RVTY	66 Neutral	$10.40B	45.85	3.04%	0.29%	3.37%	-18.80%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Idexx Laboratories Corporate Events

IDEXX Laboratories Reports Strong Q3 2025 Results

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, provides diagnostic and software products and services to support veterinary medicine and ensure the safety of milk and water worldwide. Headquartered in Maine, IDEXX employs approximately 11,000 people and serves customers in over 175 countries.

IDEXX Laboratories Appoints Karen Peacock to Board

On October 6, 2025, IDEXX Laboratories elected Karen Peacock as an independent Class I Director and appointed her to its Compensation and Talent Committee and Finance Committee. This strategic addition to the board is expected to enhance the company’s leadership with Peacock’s extensive experience in B2B, SaaS software, and AI, potentially strengthening IDEXX’s position in the pet healthcare industry.

The most recent analyst rating on (IDXX) stock is a Buy with a $745.00 price target. To see the full list of analyst forecasts on Idexx Laboratories stock, see the IDXX Stock Forecast page.

IDEXX Laboratories’ Earnings Call Highlights Strong Growth

IDEXX Laboratories’ recent earnings call reflected a strong quarter characterized by significant revenue and profit growth, primarily driven by robust international performance and record instrument placements. Despite challenges in the U.S. market, such as declining clinical visits and pressure on rapid assay revenues, the company remains optimistic about its innovation-driven strategy. This confidence is underscored by an increase in full-year guidance, indicating a positive outlook despite ongoing macroeconomic challenges.

IDEXX Laboratories Reports Strong Q2 2025 Results

IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation, providing diagnostic and software products and services to the veterinary industry, as well as ensuring the safety of milk and water worldwide. In its latest earnings report, IDEXX Laboratories announced robust financial results for the second quarter of 2025, with a reported revenue growth of 11% and organic growth of 9%, driven by strong performance in its Companion Animal Group (CAG) and Water segments. The company achieved a significant increase in earnings per share (EPS), reporting $3.63, a 49% increase from the previous year, bolstered by strategic innovations and strong commercial execution. Key highlights include a 66% increase in CAG Diagnostics capital instrument revenues and a 15% growth in IDEXX VetLab consumables. The company also updated its 2025 revenue guidance, projecting a range of $4,205 million to $4,280 million, reflecting positive foreign exchange impacts and strong recurring revenue performance. Looking ahead, IDEXX Laboratories remains optimistic about its growth prospects, with an updated EPS outlook for 2025 and continued focus on innovation and expanding its diagnostic solutions globally.